Agile Therapeutics (NASDAQ:AGRX) CEO Al Altomari takes Proactive through the company’s second-quarter results for the three months to June 30, 2022, which reveal a second consecutive quarter of increased demand for its Twirla female contraception brand and accompanying decrease in operating expenses.
Altomari told Proactive that the commercial-stage healthcare company’s mission is to provide solutions to women’s unmet medical needs.
Following the US Supreme Court’s recent overturning of Roe v. Wade and the constitutional right to abortion, Altomari said company’s like Agile have an important role to play in planned parenthood.
“We need to step up and make our products available to that community,” he said.